FreeTheAI

iBio Reports Preclinical Data Showing Enhanced Fat Loss with IBIO-610 Combo

BullishMedium impact
IBIO$0.9032 3.70%

Biotechnology firm iBio, Inc. (IBIO) released preclinical trial results demonstrating that combining its experimental drug IBIO-610 with semaglutide produced higher fat-selective weight loss in obese non-human primates. In an eight-week study of six subjects per group, animals treated with the combination lost 93% of their weight as fat compared to 77% for those receiving semaglutide alone. Lean mass loss fell to 6% in the combination group, down from 22% with semaglutide monotherapy.

Preserving lean muscle tissue remains a significant challenge for existing obesity treatments like GLP-1 receptor agonists. Treatment with IBIO-610 also led to a 97% reduction in Activin E at eight weeks, confirming target engagement. Additionally, the drug exhibited a 33.2-day half-life in primates, supporting potential for less frequent dosing schedules.

Following the news, shares of iBio rose 3.70% to $0.9032. The company plans to initiate its first human clinical trials for IBIO-610 in the first half of 2027. Investors will watch for regulatory filings and initial safety findings to determine whether the preclinical performance translates effectively to human patients.

Key points

  • Combining IBIO-610 with semaglutide resulted in 93% fat loss versus 77% with semaglutide alone in an 8-week primate study.
  • Lean mass loss decreased to 6% with the combination therapy, compared to 22% for semaglutide monotherapy.
  • IBIO-610 achieved a 97% reduction in Activin E at week eight and demonstrated a 33.2-day half-life in primates.
  • iBio plans to start first-in-human clinical trials for IBIO-610 in the first half of 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the results of iBio's IBIO-610 study?

In an 8-week study on obese primates, combining IBIO-610 with semaglutide resulted in 93% of lost weight coming from fat, compared to 77% with semaglutide alone. Lean mass loss was reduced to 6% from 22%.

When will human trials begin for IBIO-610?

iBio plans to launch first-in-human clinical trials for IBIO-610 during the first half of 2027.

How did iBio stock react to the news?

iBio, Inc. shares gained 3.70% following the announcement, trading at approximately $0.9032.